Prospective Grant of an Exclusive Patent License: Use and Development of RAB13 and NET1 Targeting Antisense Oligonucleotides in the Treatment of Cancer

Riepilogo

The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the U.S. Patents and Patent Applications listed in the Supplementary Information section of this notice to Drug Development and Filing Consulting, LLC located in Maryland, USA.